Tuberculosis Epidemiology Studies Consortium

The CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Division of Tuberculosis Elimination established this Master IDIQ on September 29, 2011, to conduct epidemiologic research on latent tuberculosis infection diagnosis and treatment, with the final date to order passing on September 28, 2020—this vehicle is no longer active and accepting new orders.

All ten task orders awarded under this vehicle executed in the initial award cycle in 2011 and completed by September 2021. The combined potential value is $41.3 million, with $41.1 million obligated (100% of potential value). No new orders have been placed since 2011, indicating the vehicle has reached the end of its useful lifecycle.

The work centers on comparing tuberculin skin testing (TST) and interferon gamma release assays (IGRAs) in diagnosing latent TB infection and predicting progression to active disease, as well as evaluating measures to enhance treatment adherence, including shorter-course preventive therapies, self-administered versus directly observed options, and targeted education programs. All task orders used cost-no-fee pricing.

Competition is distributed across ten academic and health-department contractors with no dominant prime. The largest single awards were to Denver Health and Hospital Authority ($5.1 million), California Department of Public Health ($4.7 million), and Emory University ($4.7 million). Other notable recipients include King County ($4.6 million), Duke University ($4.3 million), Maryland Department of Health ($4.2 million), and Hawaii Department of Health ($3.7 million). All orders funded CDC NCHHSTP programming, with no interagency customer activity.

All ten task orders carried no set-aside designation. Typical task-order values ranged from $3.1 million to $5.1 million. Work executed across multiple geographic sites including Colorado, California, Hawaii, Arizona, North Carolina, Maryland, Texas, and Washington State, reflecting the multi-site epidemiologic study design. This vehicle is closed to new procurement and represents completed research activity.

The Centers for Disease Control and Prevention (CDC), The Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Division of Tuberculosis Elimination Division (DTBE) has awarded a Master IDIQ for the Tuberculosis Epidemiologic Studies Consortium (TBESC) Research Project entitled, "Improving the Diagnosis and Treatment of Latent TB Infection." The project objectives are to support TBESC Research to improve the diagnosis and treatment of Latent Tuberculosis Infection (LTBI). The research study conducted includes the evaluation of: (1) Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs) in diagnosing LTBI and in predicting progression from LTBI to TB Disease; and (2) Measures to enhance adherence and completion of LTBI treatment, such as: shorter-course LTBI preventive therapy, self-administered versus directly observed preventive therapy, and education programs (either general or targeted to specific high-risk populations).